<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04982926</url>
  </required_header>
  <id_info>
    <org_study_id>TAS2940-101</org_study_id>
    <secondary_id>2021-002189-41</secondary_id>
    <nct_id>NCT04982926</nct_id>
  </id_info>
  <brief_title>A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer</brief_title>
  <official_title>A Phase 1 Study of TAS2940 in Patients With Locally Advanced or Metastatic Solid Tumors With EGFR and / or HER2 Aberrations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taiho Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taiho Oncology, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first-in-human, open label, multicenter study to assess the safety, tolerability,&#xD;
      pharmacokinetics, pharmacodynamics, and the preliminary antitumor activity of TAS2940 in&#xD;
      patients with advanced or metastatic solid tumors who are not candidates for approved or&#xD;
      available therapies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TAS2940 is a small molecule inhibitor of ERBB family proteins HER2 and EGFR. It has not been&#xD;
      evaluated in human subjects yet. The study will be conducted in 2 parts, dose escalation and&#xD;
      dose expansion. The dose escalation part will assess the safety and determine the maximum&#xD;
      tolerated dose, the recommended phase 2 dose and the recommended dosing regimen of TAS2940&#xD;
      administered orally. The dose expansion part will assess preliminary anti-tumor activity in&#xD;
      select solid tumors characterized by HER2 or EGFR aberrations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 16, 2021</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">May 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Escalation:Maximum Tolerated Dose (MTD)</measure>
    <time_frame>One Month</time_frame>
    <description>Determine the incidence of dose-liming toxicities (DLTs) and adverse events (AEs) graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0 within the first cycle</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Expansion:Overall Response Rate</measure>
    <time_frame>6 Months</time_frame>
    <description>Document the ORR, defined as proportion of patients experiencing a best overall response of Complete Response (CR) or Partial response (PR) based on investigator accessed radiographic response per RECIST 1.1 or RANO criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose Escalation: Overall Response Rate (ORR)</measure>
    <time_frame>6 Months</time_frame>
    <description>Document the ORR defined as proportion of patients experiencing a best overall response of Complete Response (CR) or Partial response (PR) based on investigator accessed radiographic response per RECIST 1.1 or RANO criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Escalation:Pharmacokinetic (PK) Profile</measure>
    <time_frame>3 Months</time_frame>
    <description>: Evaluation of the maximum observed plasma concentration; time to reach maximum concentration, area under the Concentration-time curve and time it takes for plasma concentration to fall by half its original value (T1/2) of TAS2940</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Expansion:Incidence of treatment-emergent Adverse Events (Safety and tolerability)</measure>
    <time_frame>Estimated up to 6 months</time_frame>
    <description>Safety and tolerability of TAS2940 based on reported AEs, graded according to NCI-CTCAE v.5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Expansion:Duration of Response (DOR)</measure>
    <time_frame>Estimated up to 6 months</time_frame>
    <description>DOR, defined as time from the first documentation of response to date of objective tumor progression or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Expansion:Disease Control Rate (DCR)</measure>
    <time_frame>Estimated up to 6 months</time_frame>
    <description>DCR, defined as the proportion of patients experiencing a best overall response of Stable Disease (SD), PR or CR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Expansion:Progression Free Survival (PFS)</measure>
    <time_frame>Estimated up to 6 months</time_frame>
    <description>Date of PR or CR to date of objective progression or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Expansion:Pharmacokinetic profile of TAS2940</measure>
    <time_frame>3 Months</time_frame>
    <description>Evaluation of the maximum observed plasma concentration; time to reach maximum concentration, area under the Concentration-time curve and time it takes for plasma concentration to fall by half its original value (T1/2) of TAS2940</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Solid Tumor</condition>
  <condition>Glioblastoma</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>TAS2940 Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Non-small Cell Lung Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Breast Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Gliblastoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Solid tumors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAS2940</intervention_name>
    <description>Study participants with solid tumors and EGFR or HER2 aberrations will receive TAS2940 tablets daily at increasing doses until MTD is reached.</description>
    <arm_group_label>TAS2940 Dose Escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAS2940</intervention_name>
    <description>Study subjects with select solid tumors characterized by EGFR or HER2 aberrations will receive TAS2940 at the dose identified during Dose Escalation phase.</description>
    <arm_group_label>Dose Expansion Breast Cancer</arm_group_label>
    <arm_group_label>Dose Expansion Gliblastoma</arm_group_label>
    <arm_group_label>Dose Expansion Non-small Cell Lung Cancer</arm_group_label>
    <arm_group_label>Dose Expansion Solid tumors</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have histologically confirmed solid cancer that is locally advanced and metastatic and&#xD;
             available standard treatment options have been exhausted&#xD;
&#xD;
          -  Have adequate organ function&#xD;
&#xD;
          -  ECOG PS 0-1&#xD;
&#xD;
        Dose Escalation:&#xD;
&#xD;
          -  Have measurable or non- measurable disease per RECIST criteria v1.1 or RANO&#xD;
&#xD;
          -  Any solid tumor with EGFR and / or HER2 aberration&#xD;
&#xD;
        Dose Expansion:&#xD;
&#xD;
        Have measurable disease per RECIST criteria v1.1 for solid tumor (excluding primary brain&#xD;
        tumor) or RANO (for glioblastoma)&#xD;
&#xD;
          -  Cohort A: Non-small cell lung cancer (NSCLC)&#xD;
&#xD;
          -  Cohort B: HER2 positive breast cancer&#xD;
&#xD;
          -  Cohort C: Recurrent or refractory glioblastoma&#xD;
&#xD;
          -  Cohort D: Other solid tumors with EGFR or HER2 aberrations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-stable brain metastases&#xD;
&#xD;
          -  Have significant cardiovascular disorder&#xD;
&#xD;
          -  Have not recovered from prior cancer treatment&#xD;
&#xD;
          -  A serious illness or medical condition&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Karim Benhadji, MD</last_name>
    <phone>609-250-7336</phone>
    <email>clinicaltrialinfo@taihooncology.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CLCC Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>Cedex</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 23, 2021</study_first_submitted>
  <study_first_submitted_qc>July 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2021</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

